Adapalene/Benzoyl Peroxide/Clindamycin

LAVAL, QC, July 9, 2025 – Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced that PrCABTREO™ (clindamycin phosphate, adapalene and benzoyl peroxide) gel 1.2% w/w, 0.15% w/w and 3.1% w/w, for the treatment of acne vulgaris,1 is now available to beneficiaries of the public drug plans of Ontario and Nova Scotia as well as through the federal government’s Non-Insured Health Benefits (NIHB) drug plan for Indigenous populations and that of the Correctional Service of Canada (CSC). CABTREO is a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older. CABTREO is the first and only triple-combination topical treatment for acne approved by Health Canada with three mechanisms of action – an antibiotic, a retinoid and an antibacterial agent – to provide a safe and effective treatment.1 "It is very encouraging for people with acne vulgaris who use the Ontario, Nova Scotia and federal drug plans to now have access to CABTREO along with those on most private drug insurance plans,” said Amy Cairns, General Manager, Bausch Health, Canada Inc. “We look forward to completing listing arrangements in the near future with other public drug plans across Canada.” "We are pleased that public drug plans are ensuring Canadians with acne have access to new treatments, recognizing the importance of making different options available," said Kathy Giangaspero, Executive Director of the Acne and Rosacea Society of Canada. “Acne can significantly impact a person’s mental and physical health, so this is a big win for the patient community.” CABTREO, a prescription product, is a topical gel that is administered once daily to affected areas of the skin. Its active ingredients are the antibiotic clindamycin phosphate, the topical retinoid adapalene and the oxidizing agent benzoyl peroxide with a broad-spectrum bactericidal activity.1 About Acne Vulgaris Acne vulgaris ("vulgaris" means "common") is the most common skin problem seen by doctors in Canada. It occurs when the pores of the skin become plugged with oil and skin cells, often causing whiteheads, blackheads, pimples or cysts to appear on the face, forehead, chest, upper back and shoulders. Acne affects about 5.6 million Canadians, or nearly 20 per cent of the population, including about 90 per cent of adolescents. About 25 per cent of teens will still have acne at age 25. Acne causes emotional distress and can cause permanent scarring.2 It can also cause skin pigmentation changes.3 CABTREO Clinical Data and Safety Information CABTREO was studied in two phase 3 multicentre, randomized, placebo controlled clinical trials in 363 patients with facial acne vulgaris. Both studies met all co-primary efficacy endpoints, including absolute change from baseline in inflammatory lesion count, absolute change from baseline in non-inflammatory lesion count, and percentage of patients achieving pre-defined treatment success. Combined efficacy results for both trials for CABTREO achieved approximately 50% treatment success and a greater than 70% reduction in both inflammatory and noninflammatory lesions at Week 12.1 The most frequent adverse reactions that may occur with CABTREO are mild to moderate application site reactions, such as skin irritation characterized by scaling, dryness, erythema, and burning/stinging. CABTREO should not be used by those who are hypersensitive to any of the ingredients in it (clindamycin phosphate, adapalene, benzoyl peroxide or to any ingredient in the formulation), patients with a history of regional enteritis (Crohn’s disease), ulcerative colitis or antibiotic-associated colitis or by pregnant women and women planning a pregnancy. CABTREO may bleach hair and coloured fabric so caution should be used when applying it near the hairline.1 Health Canada has not authorized CABTREO for pediatric use under the age of 12 years. CABTREO is for topical use only and is not for oral, ophthalmic or intravaginal use.1 About Dermatology at Bausch Health, Canada Inc. Bausch Health, Canada Inc. has one of the largest prescription dermatology businesses in Canada dedicated to helping patients in the treatment of a range of therapeutic areas, including psoriasis, actinic keratosis, acne, atopic dermatitis and other dermatoses. The Bausch Health, Canada Inc. dermatology portfolio includes several leading acne, psoriasis, anti-fungal and corticosteroid-responsive dermatoses products. CABTREO is the fourth new dermatology treatment from Bausch Health, Canada Inc. approved by Health Canada and made available to Canadians over the past four years, adding to the company's leading portfolio in this important treatment area. The other approvals were for ARAZLO™ (tazarotene lotion, 0.045% w/w), for the topical treatment of acne vulgaris in patients 10 years of age and older; BRYHALI™ (halobetasol propionate lotion 0.01% w/w), for corticosteroid-responsive dermatoses and the topical treatment of plaque psoriasis in adults; and DUOBRII™ (0.01% w/w halobetasol propionate and 0.045% w/w tazarotene) to treat adults with moderate to severe plaque psoriasis.4 All four treatments – CABTREO, ARAZLO, BRYHALI and DUOBRII – are manufactured at Bausch Health's Laval, Quebec, facility for Canada and the United States. About Bausch Health Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn. The Bausch Health Canadian prescription treatment portfolio is focused on dermatology, gastrointestinal and cardio-metabolic conditions. Bausch Health also has two manufacturing facilities for prescription pharmaceuticals in Canada: in Laval, Quebec, and Steinbach, Manitoba. More information can be found at the Company's website at www.bauschhealth.ca. Forward-looking Statements This news release may contain forward-looking statements within the meaning of applicable securities laws, including the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of the words “will,” “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “subject to” and variations or similar expressions. These statements are neither historical facts nor assurances of future performance, are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual and quarterly reports and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to update any of these forward-looking statements to reflect events, information or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. REFERENCES 1 Bausch Health, Canada Inc., CABTREO Product Monograph, https://pdf.hres.ca/dpd_pm/00076715.PDF. 2 Canadian Dermatology Association, Acne, Quick Facts, https://dermatology.ca/public-patients/skin/acne/#:~:text=Acne%20affects%205.6%20million%20Canadians,adults%20ages%2020%20to%2040, accessed Aug. 20, 2024. 3 "What to Know about Hyperpigmentation Acne." Medical News Today, Jessica Caporuscio, April 28, 2021, https://www.medicalnewstoday.com/articles/hyperpigmentation-acne, accessed Aug. 20, 2024. 4 Bausch Health, Canada Inc., Canadian Product List, https://bauschhealth.ca/products/canadian-product-list/.

First quarter revenues of $2.15 billion, up 11% on a Reported and 8% on an Organic1 basis Year-over-year revenue growth in all segments on both a Reported and Organic1 Basis GAAP Net Loss Attributable to Bausch Health Companies Inc. of $64 Million Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $665 Million, up 13% Xifaxan® Appeal Decision Represents a Significant Milestone related to Full Separation of Bausch + Lomb Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidance LAVAL, QC / ACCESSWIRE / May 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company" or "we" or "our") today announced its first quarter 2024 financial results and other key updates from the quarter. "We are pleased with our strong start to the year, delivering solid first-quarter performance, and our fourth consecutive quarter of year-over-year growth in revenues and adjusted EBITDA. Furthermore, all our business segments posted year-over-year revenue growth on both a reported and organic basis. I'm very proud of what our team has accomplished and we remain focused on continuing our momentum by advancing our R&D pipeline, strengthening our balance sheet and executing on our commercial strategies to drive global growth," said Thomas J. Appio, Chief Executive Officer, Bausch Health. "We are also pleased with other key developments for our business during the quarter, including the appeal decision in the Norwich matter in respect of Xifaxan®, which represents a significant milestone as it relates to achieving the full separation of Bausch + Lomb. "We will continue to focus on the foundation we set across the enterprise to deliver results and improve the health of patients worldwide," continued Mr. Appio. 1 This is a non-GAAP measure or a non-GAAP ratio. For further information on non-GAAP measures and non-GAAP ratios, please refer to the "Non-GAAP Information" section of this news release. Please also refer to tables at the end of this news release for a reconciliation of this and other non-GAAP measures to the most directly comparable GAAP measure. Bausch Health (excl. B+L) R&D Update Amiselimod (S1P modulator): once-daily oral treatment of mild to moderate ulcerative colitis Positive top-line Phase 2 data results announced in December 2023 Selected for Podium Presentation at Digestive Disease Week 2024 Conference on May 19 Met with the U.S. Food and Drug Administration ("FDA") for end of Phase 2 meeting and Phase 3 planning for mild to severe UC patients, with plans to meet with other international authorities Advancing plans for Phase 2 study for Crohn's disease RED-C: prevention and delay of first episode of hepatic encephalopathy Enrollment of the second global Phase 3 trial completed in April 2024. Enrollment of both global Phase 3 studies are now complete and currently in the treatment phase CABTREO®: first triple combination product for the treatment of acne vulgaris U.S. commercial launch in late January 2024 New Drug Submission was submitted to Health Canada on May 30, 2023 with anticipated approval in the second half of 2024 Thermage® FLX: uses radiofrequency technology to help tighten and improve the smoothness and texture of the skin's surface Thermage® FLX and the TR-4 Return Pad approved by China's National Medical Products Administration in January 2024 Clear + Brilliant® Touch: fractionated laser device for skin rejuvenation Planned regulatory submissions on track for Europe, Canada, and Asia Pacific markets in 2024 Approved in Australia and New Zealand - first approvals outside of the U.S. Next Generation Fraxel®: fractionated laser device for skin resurfacing FDA submission planned in Q2 2024 and approval could occur in the second half of 2024 Xifaxan® Appeal Decision Reinforces the Company's Salix Growth Strategy On April 11, 2024, the U.S. Court of Appeals for the Federal Circuit affirmed the decision of the U.S. District Court for the District of Delaware in the Norwich matter. In its ruling, the Court denied Norwich Pharmaceuticals, Inc.'s motion for modification of the court's final order. As a result, the FDA cannot approve Norwich's abbreviated new drug application for Xifaxan® (rifaximin) 550 mg until October 2029. The Company will continue to vigorously defend its intellectual property. First Quarter 2024 Revenue Performance Total reported revenues were $2.15 billion for the first quarter of 2024, compared with $1.94 billion in the first quarter of 2023, an increase of $209 million, or 11%. Excluding the impact of foreign exchange of $8 million, acquisitions of $88 million, and divestitures and discontinuations of $18 million, revenue increased by 8% organically1 compared with the first quarter of 2023. Reported revenues by segment were as follows: Three Months Ended March 31, Reported Change (in millions) 2024 2023 Amount Pct. Change at Constant Currency1 (Non-GAAP) Change in Organic Revenue1 (Non-GAAP) Total Bausch Health Revenues $ 2,153 $ 1,944 $ 209 11 % 11 % 8 % Bausch Health (excl. B+L) $ 1,054 $ 1,013 $ 41 4 % 3 % 5 % Salix segment $ 499 $ 496 $ 3 1 % 1 % 2 % International segment $ 265 $ 247 $ 18 7 % 2 % 2 % Solta Medical segment $ 88 $ 73 $ 15 21 % 23 % 23 % Diversified segment $ 202 $ 197 $ 5 3 % 3 % 6 % Bausch + Lomb segment $ 1,099 $ 931 $ 168 18 % 20 % 11 % Salix Segment Salix segment reported revenues were $499 million for the first quarter of 2024, compared with $496 million for the first quarter of 2023, an increase of $3 million, or 1%. Excluding the impact of divestitures and discontinuations of $9 million, segment revenues increased 2% on an organic1 basis. Sales growth was driven by Xifaxan® and Relistor®, partially offset by net pricing pressures for Trulance® and certain non-promoted products. International Segment International segment reported revenues were $265 million for the first quarter of 2024, compared with $247 million for the first quarter of 2023, an increase of $18 million, or 7%. Excluding the impact of foreign exchange of $14 million and divestitures and discontinuations of $1 million, segment revenues increased organically1 by 2% compared with the first quarter of 2023, led by growth in Canada. Solta Medical Segment Solta Medical segment reported revenues were $88 million for the first quarter of 2024, compared with $73 million in the first quarter of 2023, an increase of $15 million, or 21%, which was driven by growth in the Asia Pacific region and, to a lesser degree, the U.S. Excluding the impact of foreign exchange of $2 million, segment revenues increased organically1 by 23% compared with the first quarter of 2023. Diversified Segment Diversified segment reported revenues were $202 million for the first quarter of 2024, compared with $197 million for the first quarter of 2023, an increase of $5 million, or 3%. Excluding the impact of divestitures and discontinuations of $6 million, segment revenues increased 6% on an organic 1 basis, primarily attributable to increases in sales in Dermatology and Neurology. Bausch + Lomb Segment Bausch + Lomb segment reported revenues were $1,099 million for the first quarter of 2024, compared with $931 million for the first quarter of 2023, an increase of $168 million, or 18%. Excluding the impact of foreign exchange of $20 million, acquisitions of $88 million and divestitures and discontinuations of $2 million, the Bausch + Lomb segment revenue increased organically1 by 11% compared with the first quarter of 2023, driven by increases across all business units. Consolidated Operating Income Consolidated operating income was $281 million for the first quarter of 2024, compared with operating income of $175 million for the first quarter of 2023, an increase of $106 million. The change was primarily due to the effect of higher revenues and associated gross profit, which was partially offset by higher selling and advertising and promotion expenses, as well as investments in research and development. Net Loss Attributable to Bausch Health Net loss attributable to Bausch Health for the first quarter of 2024 was $64 million, compared with $201 million for the first quarter of 2023, a decrease of $137 million, primarily due to the increase in Operating Income and a gain on extinguishment of debt of $11 million recorded in the first quarter of 2024, partially offset by higher interest expense. Adjusted net income attributable to Bausch Health (non-GAAP)1 for the first quarter of 2024 was $221 million, compared with $191 million for the first quarter of 2023, an increase of $30 million, primarily due to higher revenues and gross profit, partially offset by higher selling and advertising and promotion expenses, investments in research and development and higher interest expense. Net Loss Per Share Attributable to Bausch Health GAAP net loss per share attributable to Bausch Health for the first quarter of 2024 was ($0.17), compared with ($0.55) for the first quarter of 2023. Adjusted EBITDA Attributable to Bausch Health (non-GAAP)1 Adjusted EBITDA attributable to Bausch Health (non-GAAP)1 was $665 million for the first quarter of 2024, as compared to $588 million for the first quarter of 2023, an increase of $77 million. Cash Provided by Operating Activities The Company generated $211 million of cash from operating activities in the first quarter of 2024 compared with cash generated of $154 million in the first quarter of 2023. The increase in cash flow reflected improved operating results as discussed above. Balance Sheet Highlights as of March 31, 2024: Cash and cash equivalents of $755 million. Bausch Health (excl. B+L) had availability under its 2027 revolving credit facility of approximately $950 million and Bausch + Lomb had availability of approximately $175 million under its revolving credit facility. Bausch Health (excl. B+L) has an accounts receivable credit facility which provides for up to $600 million of availability, subject to certain borrowing base tests, $325 million of which was drawn as of March 31, 2024. Bausch Health is focused on strengthening its balance sheet, including evaluating and utilizing as appropriate various tools and strategies, based on the provisions of its existing debt agreements, to further reduce the company's outstanding debt and enhance its debt maturity profile. 2024 Financial Outlook The Company reaffirmed its full-year revenue and Adjusted EBITDA (non-GAAP)1 guidance: Current Guidance (as of May 2, 2024) BHC BHC (excl. B+L) B+L Revenues (in Billions) $9.300 - $9.550 $4.700 - $4.850 $4.600 - $4.700 Organic1 growth vs. Prior Year 2%-5% Adjusted EBITDA1 (in Billions) $3.20 - $3.35 $2.36 - $2.46 $0.84 - $0.89 Other than with respect to GAAP revenues, the Company only provides guidance on a non-GAAP basis. The Company does not provide a reconciliation of forward-looking Adjusted EBITDA (non-GAAP)1 to GAAP net income (loss), due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Because deductions (such as restructuring, gain or loss on extinguishment of debt and litigation and other matters) used to calculate projected net income (loss) vary dramatically based on actual events, the Company is not able to forecast on a GAAP basis with reasonable certainty all deductions needed in order to provide a GAAP calculation of projected net income (loss) at this time. The amount of these deductions may be material and, therefore, could result in projected GAAP net income (loss) being materially less than projected Adjusted EBITDA (non-GAAP)1. These statements represent forward-looking information and may represent a financial outlook, and actual results may vary. Please see the risks and assumptions referred to in the "Forward-looking Statements" section of this news release. The guidance in this news release is only effective as of the date it is given and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance. Conference Call Details Date: Thursday, May 2, 2024 Time: 8:00 a.m. ET Webcast: A replay of the conference call will be available on the investor relations website. About Bausch Health Bausch Health Companies Inc. (NYSE/TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit and connect with us on Twitter and LinkedIn. Forward-looking Statements This news release contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forward-looking statements"), including, but not limited to, statements relating to the Company's: future prospects and performance, financial guidance, research and development efforts and anticipated timing or results thereof, proposed plan to separate its eye health business, including the timing thereof, management of its balance sheet, generation of cash, ability to launch and commercialize new products, including the timing of regulatory processes with respect to the Company's product pipeline, ability to enforce and defend its Xifaxan® intellectual property rights, ability to execute its growth strategies generally, and other corporate and strategic transactions. Forward-looking statements may generally be identified by the use of the words "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and positive and negative variations or similar expressions, and phrases or statements that certain actions, events or results may, could, should or will be achieved, received or taken, or will occur or result, and similar such expressions also identify forward-looking information. These forward-looking statements are based upon the current expectations and beliefs of management. The Company's 2024 financial outlook and full-year guidance are included to provide further information about management's expectations about the Company's future business operations, activities and results and may not be appropriate for other purposes. These forward-looking statements are subject to certain factors, risks and uncertainties that could cause actual results to differ materially from those described in these forward-looking statements. These factors, risks and uncertainties include, but are not limited to the following: the impact of current market and economic conditions in one or more of the Company's markets; the impact of inflation and other macroeconomic factors on the Company's business and operations; the ability to complete the separation of Bausch + Lomb, including the timing and structure thereof, and to achieve the expected benefits thereof, and other risks and uncertainties relating to such separation, including actual and potential litigation related thereto; uncertainty of commercial success for new and existing products; challenges to patents; challenges to the Company's ability to enforce and defend against challenges to its patents; the impact of patent expirations and the ability of the company to successfully execute strategic plans; compliance with legal and regulatory requirements; our substantial debt and current and future debt service obligations; and other factors, risks and uncertainties discussed in the Company's most recent annual and quarterly reports and detailed from time to time in the Company's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors, risks and uncertainties are incorporated herein by reference. Additional information regarding certain of these material factors and assumptions may be found in the Company's filings described above. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable in the circumstances, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. Non-GAAP Information To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures and non-GAAP ratios to provide supplemental information to readers. Management uses these non-GAAP measures and ratios as key metrics in the evaluation of the Company's performance and the consolidated financial results and, in part, in the determination of cash bonuses for its executive officers. The Company believes these non-GAAP measures and ratios are useful to investors in their assessment of our operating performance and the valuation of the Company. In addition, these non-GAAP measures and ratios address questions the Company routinely receives from analysts and investors, and in order to assure that all investors have access to similar data, the Company has determined that it is appropriate to make this data available to all investors. However, these measures and ratios are not prepared in accordance with GAAP nor do they have any standardized meaning under GAAP. In addition, other companies may use similarly titled non-GAAP financial measures and ratios that are calculated differently from the way we calculate such measures and ratios. Accordingly, our non-GAAP financial measures and ratios may not be comparable to such similarly titled non-GAAP financial measures and ratios used by other companies. We caution investors not to place undue reliance on such non-GAAP measures and ratios, but instead to consider them with the most directly comparable GAAP measures and ratios. Non-GAAP financial measures and ratios have limitations as analytical tools and should not be considered in isolation. They should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. The reconciliations of these historic non-GAAP financial measures and ratios to the most directly comparable financial measures and ratios calculated and presented in accordance with GAAP are shown in the tables below. However, as indicated above, for guidance purposes, the Company does not provide reconciliations of projected Adjusted EBITDA (non-GAAP) to projected GAAP Net income (loss), due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations. Specific Non-GAAP Measures Adjusted EBITDA (non-GAAP) and Adjusted EBITDA attributable to Bausch Health (non-GAAP) Adjusted EBITDA (non-GAAP) is Net income (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (Benefit from) provision for income taxes, depreciation and amortization and certain other items described below. Adjusted EBITDA attributable to Bausch Health (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) as defined below. Management believes that Adjusted EBITDA (non-GAAP) and Adjusted EBITDA attributable to Bausch Health (non-GAAP), along with the GAAP measures used by management, most appropriately reflect how the Company measures the business internally and sets operational goals and incentives. In particular, the Company believes that these metrics focus management of the Company's underlying operational results and business performance. As a result, the Company uses these metrics to assess the financial performance of the Company and to forecast future results as part of its guidance. Management believes these metrics are a useful measure to evaluate current performance. These metrics are intended to show our unleveraged, pre-tax operating results and therefore reflects our financial performance based on operational factors. In addition, cash bonuses for the Company's executive officers and other key employees are based, in part, on the achievement of certain Adjusted EBITDA (non-GAAP) targets. Adjusted EBITDA (non-GAAP) is Net income (loss) (its most directly comparable GAAP financial measure) adjusted for interest expense, net, (Benefit from) provision for income taxes, depreciation and amortization and the following items: Goodwill impairments: The Company excludes the impact of goodwill impairments. When the Company has made acquisitions where the consideration paid was in excess of the fair value of the net assets acquired, the remaining purchase price is recorded as goodwill. For assets that we developed ourselves, no goodwill is recorded. Goodwill is not amortized but is tested for impairment. The amount of goodwill impairment is measured as the excess of a reporting unit's carrying value over its fair value. Management excludes these charges in measuring the performance of the Company and the business. Asset impairments: The Company has excluded the impact of impairments of finite-lived and indefinite-lived intangible assets, as well as impairments of assets held for sale, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions and divestitures. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes impairments of intangible assets and assets held for sale from measuring the performance of the Company and the business, the Company believes that it is important for investors to understand that intangible assets contribute to revenue generation. Restructuring, integration and transformation costs: The Company has incurred restructuring costs as it implemented certain strategies, which involved, among other things, improvements to its infrastructure and operations, internal reorganizations and impacts from the divestiture of assets and businesses. With regard to infrastructure and operational improvements which the Company has taken to improve efficiencies in the businesses and facilities, these tend to be costs intended to right size the business or organization that fluctuate significantly between periods in amount, size and timing, depending on the improvement project, reorganization or transaction. Additionally, with the completion of the B+L IPO, as the Company prepares for post-separation operations, the Company is launching certain transformation initiatives that will result in certain changes to and investment in its organizational structure and operations. These transformation initiatives arise outside of the ordinary course of continuing operations and, as is the case with the Company's restructuring efforts, costs associated with these transformation initiatives are expected to fluctuate between periods in amount, size and timing. These out-of-the-ordinary-course charges include third-party advisory costs, as well as certain severance-related costs (including the severance costs associated with the departure of Bausch + Lomb's former CEO). Investors should understand that the outcome of these transformation initiatives may result in future restructuring actions and certain of these charges could recur. The Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors. Acquisition-related costs and adjustments (excluding amortization of intangible assets): The Company has excluded the impact of acquisition-related costs and fair value inventory step-up resulting from acquisitions as the amounts and frequency of such costs and adjustments are not consistent and are significantly impacted by the timing and size of its acquisitions. In addition, the Company excludes acquisition-related contingent consideration non-cash adjustments due to the inherent uncertainty and volatility associated with such amounts based on changes in assumptions with respect to fair value estimates, and the amount and frequency of such adjustments are not consistent and are significantly impacted by the timing and size of the Company's acquisitions, as well as the nature of the agreed-upon consideration. Gain (loss) on extinguishment of debt: The Company has excluded gain (loss) on extinguishment of debt as this represents a gain or loss from refinancing our existing debt and is not a reflection of our operations for the period. Further, the amount and frequency of such amounts are not consistent and are significantly impacted by the timing and size of debt financing transactions and other factors in the debt market out of management's control. Share-based compensation: The Company has excluded costs relating to share-based compensation. The Company believes that the exclusion of share-based compensation expense assists investors in the comparisons of operating results to peer companies. Share-based compensation expense can vary significantly based on the timing, size and nature of awards granted. Separation costs and separation-related costs: The Company has excluded certain costs incurred in connection with activities regarding the separation of the eye-health business. Separation costs are incremental costs directly related to effectuating the separation of the eye-health business, and include, but are not limited to, legal, audit and advisory fees. Separation-related costs are incremental costs indirectly related to the separation of the eye-health business and include, but are not limited to, rebranding costs and costs associated with facility relocation and/or modification. As these costs arise from events outside of the ordinary course of continuing operations, the Company believes that the adjustments of these items provide supplemental information with regard to the sustainability of the Company's operating performance, allow for a comparison of the financial results to historical operations and forward-looking guidance and, as a result, provide useful supplemental information to investors. Other adjustments: The Company has excluded certain other amounts, including legal and other professional fees incurred in connection with legal and governmental proceedings, investigations and information requests regarding certain of our legacy distribution, marketing, pricing, disclosure and accounting practices, litigation and other matters, and net (gain) loss on sale of assets or other disposition of assets. Given the unique nature of the matters relating to these costs, the Company believes these items are not normal operating expenses. For example, legal settlements and judgments vary significantly, in their nature, size and frequency, and, due to this volatility, the Company believes the costs associated with legal settlements and judgments are not normal operating expenses. In addition, as opposed to more ordinary course matters, the Company considers that each of the recent proceedings, investigations and information requests, given their nature and frequency, are outside of the ordinary course and relate to unique circumstances. The Company has also excluded IT infrastructure investments that are the result of other, non-comparable events to measure operating performance. These events arise outside of the ordinary course of continuing operations. The Company has also excluded certain other costs, including professional fees associated with contemplated, but not completed, strategic transactions. The Company excluded these costs as the consideration of such matters are outside of the ordinary course of continuing operations and are infrequent in nature. The Company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the Company from period to period and, therefore, provides useful supplemental information to investors. However, investors should understand that many of these costs could recur and that companies in our industry often face litigation. Adjusted EBITDA attributable to Bausch Health (non-GAAP) is Adjusted EBITDA (non-GAAP) further adjusted to exclude the Adjusted EBITDA attributable to noncontrolling interest (non-GAAP). Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) is Net income (loss) attributable to noncontrolling interest (its most directly comparable GAAP financial measure) adjusted for the portion of the adjustments described above attributable to noncontrolling interest. Adjusted Net Income (non-GAAP) and Adjusted Net Income attributable to Bausch Health (non-GAAP) Adjusted net income (non-GAAP) is Net income (its most directly comparable GAAP financial measure), adjusted for asset impairments, goodwill impairments, restructuring, integration and transformation costs, acquisition-related costs and adjustments (excluding amortization of intangible assets), gain (loss) on extinguishment of debt, separation costs and separation-related costs and other non-GAAP adjustments as these adjustments are described above, and amortization of intangible assets and acquisition-related costs and adjustments excluding amortization of intangible assets, as described below: Amortization of intangible assets: The Company has excluded the impact of amortization of intangible assets, as such amounts are inconsistent in amount and frequency and are significantly impacted by the timing and/or size of acquisitions. The Company believes that the adjustments of these items correlate with the sustainability of the Company's operating performance. Although the Company excludes the amortization of intangible assets from its non-GAAP expenses, the Company believes that it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in the amortization of additional intangible assets. Acquisition-related costs and adjustments excluding amortization of intangible assets: In addition to the acquisition-related costs and adjustments as described above, the Company has excluded the expense directly attributable to one-time commitment and structuring fees related to a bridge loan facility put in place prior to the acquisition of XIIDRA and certain other ophthalmology assets. The company excluded these costs as they are outside of the ordinary course of continuing operations and are infrequent in nature. The Company believes that the exclusion of such out-of-the-ordinary-course amounts provides supplemental information to assist in the comparison of the financial results of the company from period to period and, therefore, provides useful supplemental information to investors. Adjusted net income attributable to Bausch Health (non-GAAP) is Adjusted net income (non-GAAP) further adjusted to exclude the Adjusted net income attributable to noncontrolling interest (non-GAAP). Adjusted net income attributable to noncontrolling interest (non-GAAP) is Net income attributable to noncontrolling interest (its most directly comparable GAAP financial measure) adjusted for the portion of the adjustments described above attributable to noncontrolling interest. Historically, management has used Adjusted net income (loss) (non-GAAP) for strategic decision making, forecasting future results and evaluating current performance. This non-GAAP measure excludes the impact of certain items (as described above) that may obscure trends in the Company's underlying performance. By disclosing this non-GAAP measure, it is management's intention to provide investors with a meaningful, supplemental comparison of the Company's operating results and trends for the periods presented. Management believes that this measure is also useful to investors as such measure allows investors to evaluate the Company's performance using the same tools that management uses to evaluate past performance and prospects for future performance. Accordingly, the Company believes that Adjusted net income (non-GAAP) is useful to investors in their assessment of the Company's operating performance. It is also noted that, in recent periods, our GAAP Net income (loss) was significantly lower than our Adjusted net income (non-GAAP). Organic Revenue (non-GAAP) and Change in Organic Revenue (non-GAAP) Organic revenue (non-GAAP) and Change in organic revenue (non-GAAP), are defined as GAAP Revenue and change in GAAP Revenue (the most directly comparable GAAP financial measures), adjusted for changes in foreign currency exchange rates (if applicable) and excluding the impact of recent acquisitions, divestitures and discontinuations, as defined below. Organic revenue (non-GAAP) is impacted by changes in product volumes and price. The price component is made up of two key drivers: (i) changes in product gross selling price and (ii) changes in sales deductions. The Company uses organic revenue (non-GAAP) and change in organic revenue (non-GAAP) to assess performance of its reportable segments, and the Company in total. The Company believes that providing these non-GAAP measures is useful to investors as they provide a supplemental period-to-period comparison. The adjustments to GAAP Revenue to determine Organic Revenue (non-GAAP) and Change in Organic Revenue (non-GAAP) are as follows: Foreign currency exchange rates: Although changes in foreign currency exchange rates are part of our business, they are not within management's control. Changes in foreign currency exchange rates, however, can mask positive or negative trends in the business. The impact of changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period. Acquisitions, divestitures and discontinuations: In order to present period-over-period organic revenue (non-GAAP) growth/change on a comparable basis, revenues associated with acquisitions, divestitures and discontinuations are adjusted to include only revenues from those businesses and assets owned during both periods. Accordingly, organic revenue and change in organic revenue exclude from the current period, revenues attributable to each acquisition for twelve months subsequent to the day of acquisition, as there are no revenues from those businesses and assets included in the comparable prior period. Organic revenue and change in organic revenue exclude from the prior period, all revenues attributable to each divestiture and discontinuance during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period. Constant Currency Changes in the relative values of non-U.S. currencies to the U.S. dollar may affect the Company's financial results and financial position. To assist investors in evaluating the Company's performance, we have adjusted for the effects of changes in foreign currencies. The impact of changes in foreign currency exchange rates is determined by comparing the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period. Please also see the reconciliation tables below for further information as to how these non-GAAP measures and ratios are calculated for the periods presented. Investor Contact: Media Contact: Garen Sarafian Kevin Wiggins ir@bauschhealth.com corporate.communications@bauschhealth.com (877) 281-6642 (toll free) (908) 541-3785 FINANCIAL TABLES FOLLOW Bausch Health Companies Inc. Condensed Consolidated Statements of Operations For the Three Months Ended March 31, 2024 and 2023 (unaudited) Table 1 Three Months Ended March 31, (in millions) 2024 2023 Revenues Product sales $ 2,129 $ 1,922 Other revenues 24 22 2,153 1,944 Expenses Cost of goods sold (excluding amortization and impairments of intangible assets) 628 572 Cost of other revenues 12 10 Selling, general and administrative 794 725 Research and development 151 143 Amortization of intangible assets 274 273 Asset impairments 1 13 Restructuring, integration and separation costs 12 10 Other expense, net - 23 1,872 1,769 Operating income 281 175 Interest income 9 6 Interest expense (355 ) (307 ) Gain on extinguishment of debt 11 - Foreign exchange and other (15 ) (10 ) Loss before income taxes (69 ) (136 ) Provision for income taxes (8 ) (73 ) Net loss (77 ) (209 ) Net loss attributable to noncontrolling interest 13 8 Net loss attributable to Bausch Health Companies Inc. $ (64 ) $ (201 ) Bausch Health Companies Inc. Reconciliation of GAAP Net Loss to Adjusted Net Income (non-GAAP) For the Three Months Ended March 31, 2024 and 2023 (unaudited) Table 2 Three Months Ended March 31, (in millions) 2024 2023 Net loss $ (77 ) $ (209 ) Non-GAAP adjustments:(a) Amortization of intangible assets 274 273 Asset impairments 1 13 Restructuring, integration and transformation costs 19 27 Acquisition-related costs and adjustments (excluding amortization of intangible assets) 18 31 Gain on extinguishment of debt (11 ) - IT infrastructure investment 10 7 Separation costs and separation-related costs 6 7 Legal and other professional fees 6 3 Gain on sale of assets, net (4 ) - Litigation and other matters, net of insurance recoveries 6 (8 ) Other 7 - Tax effect of non-GAAP adjustments (31 ) 49 Total non-GAAP adjustments 301 402 Adjusted net income (non-GAAP) 224 193 Adjusted net income attributable to noncontrolling interest (non-GAAP) (3 ) (2 ) Adjusted net income attributable to Bausch Health Companies Inc. (non-GAAP) $ 221 $ 191 (a) The components of and further details respecting each of these non-GAAP adjustments and the financial statement line item to which each component relates can be found on Table 2a. Bausch Health Companies Inc. Reconciliation of GAAP to Non-GAAP Financial Information For the Three Months Ended March 31, 2024 and 2023 (unaudited) Table 2a Three Months Ended March 31, (in millions) 2024 2023 Cost of goods sold reconciliation: GAAP Cost of goods sold (excluding of amortization and impairments of intangible assets) $ 628 $ 572 Fair value inventory step-up resulting from acquisitions(a) (20 ) - Adjusted cost of goods sold (excluding of amortization and impairments of intangible assets) (non-GAAP) $ 608 $ 572 Selling, general and administrative reconciliation: GAAP Selling, general and administrative $ 794 $ 725 IT infrastructure investment(b) (10 ) (7 ) Legal and other professional fees(c) (6 ) (3 ) Separation-related costs(d) (5 ) (6 ) Transformation costs(e) (7 ) (18 ) Adjusted selling, general and administrative (non-GAAP) $ 766 $ 691 Research and development reconciliation: GAAP Research and development $ 151 $ 143 Separation-related costs(d) (1 ) - Adjusted research and development (non-GAAP) $ 150 $ 143 Amortization of intangible assets reconciliation: GAAP Amortization of intangible assets $ 274 $ 273 Amortization of intangible assets(f) (274 ) (273 ) Adjusted amortization of intangible assets (non-GAAP) $ - $ - Asset impairments: GAAP Asset impairments $ 1 $ 13 Asset impairments(g) (1 ) (13 ) Adjusted asset impairments (non-GAAP) $ - $ - Restructuring, integration and separation costs reconciliation: GAAP Restructuring, integration and separation costs $ 12 $ 10 Restructuring and integration costs(e) (12 ) (9 ) Separation costs(d) - (1 ) Adjusted restructuring, integration and separation costs (non-GAAP) $ - $ - Bausch Health Companies Inc. Reconciliation of GAAP to Non-GAAP Financial Information For the Three Months Ended March 31, 2024 and 2023 (unaudited) Table 2a (continued) Three Months Ended March 31, (in millions) 2024 2023 Other expense, net reconciliation: GAAP Other expense, net $ - $ 23 Litigation and other matters, net of insurance recoveries(h) (6 ) 8 Acquisition-related contingent consideration(a) 2 (31 ) Gain on sale of assets, net(i) 4 - Adjusted other expense, net (non-GAAP) $ - $ - Gain on extinguishment of debt reconciliation: GAAP Gain on extinguishment of debt $ 11 $ - Gain on extinguishment of debt(j) (11 ) - Adjusted gain on extinguishment of debt (non-GAAP) $ - $ - Foreign exchange and other reconciliation: GAAP Foreign exchange and other $ (15 ) $ (10 ) Other professional fees(k) (7 ) - Adjusted foreign exchange and other (non-GAAP) $ (22 ) $ (10 ) Provision for income taxes reconciliation: GAAP Provision for income taxes $ (8 ) $ (73 ) Tax effect of non-GAAP adjustments(l) (31 ) 49 Adjusted provision for income taxes (non-GAAP) $ (39 ) $ (24 ) Net loss (income) attributable to noncontrolling interest reconciliation: GAAP Net loss attributable to noncontrolling interest $ 13 $ 8 Noncontrolling interest portion of amortization of intangible asset (m) (8 ) (6 ) Noncontrolling interest portion of all other adjustments(m) (8 ) (4 ) Adjusted net income attributable to noncontrolling interest (non-GAAP) $ (3 ) $ (2 ) (a) Represents the two components of the non-GAAP adjustment of "Acquisition-related costs and adjustments (excluding amortization of intangible assets)" (see Table 2). (b) Represents the sole component of the non-GAAP adjustment of "IT infrastructure investment" (see Table 2). (c) Represents the sole component of the non-GAAP adjustment of "Legal and other professional fees" (see Table 2). (d) Represents the two components of the non-GAAP adjustment of "Separation costs and separation-related costs" (see Table 2). (e) Represents the two components of the non-GAAP adjustment of "Restructuring, integration and transformation costs" (see table 2). (f) Represents the sole component of the non-GAAP adjustment of "Amortization of intangible assets" (see Table 2). (g) Represents the sole component of the non-GAAP adjustment of "Asset impairments" (see Table 2). (h) Represents the sole component of the non-GAAP adjustment of "Litigation and other matters, net of insurance recoveries" (see Table 2). (i) Represents the sole component of the non-GAAP adjustment of "Gain on sale of assets, net" (see Table 2). (j) Represents the sole component of the non-GAAP adjustment of "Gain on extinguishment of debt" (see Table 2). (k) Represents the sole component of the non-GAAP adjustment of "Foreign exchange and other" (see Table 2). (l) Represents the sole component of the non-GAAP adjustment of "Tax effect of non-GAAP adjustments" (see Table 2). (m) Represents the portion of the non-GAAP adjustments above attributable to noncontrolling interest (see Table 2). Bausch Health Companies Inc. Reconciliation of GAAP Net Loss to Adjusted EBITDA (non-GAAP) For the Three Months Ended March 31, 2024 and 2023 (unaudited) Table 2b Three Months Ended March 31, (in millions) 2024 2023 Net loss $ (77 ) $ (209 ) Interest expense, net 346 301 Provision for income taxes 8 73 Depreciation and amortization 320 319 EBITDA 597 484 Adjustments: Asset impairments 1 13 Restructuring, integration and transformation costs 19 27 Acquisition-related costs and adjustments (excluding amortization of intangible assets) 18 31 Gain on extinguishment of debt (11 ) - Share-based compensation 33 41 Separation costs and separation-related costs 6 7 Other adjustments: Litigation and other matters, net of insurance recoveries 6 (8 ) IT infrastructure investment 10 7 Legal and other professional fees(a) 6 3 Gain on sale of assets, net (4 ) - Other 7 - Adjusted EBITDA (non-GAAP) 688 605 Adjusted EBITDA attributable to noncontrolling interest (non-GAAP)(b) (23 ) (17 ) Adjusted EBITDA attributable to Bausch Health Companies Inc. (non-GAAP) $ 665 $ 588 (a) Legal and other professional fees incurred during the three months ended March 31, 2024 and 2023 in connection with recent legal and governmental proceedings, investigations and information requests related to, among other matters, our distribution, marketing, pricing, disclosure and accounting practices. (b) Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) is Net loss attributable to noncontrolling interest adjusted for the noncontrolling interest portion of the adjustments above as follows: Three Months Ended March 31, (in millions) 2024 2023 Net loss attributable to noncontrolling interest $ 13 $ 8 Noncontrolling interest portion of adjustments for: Interest expense, net (11 ) (6 ) Depreciation and amortization (12 ) (10 ) All other adjustments (13 ) (9 ) Adjusted EBITDA attributable to noncontrolling interest (non-GAAP) $ (23 ) $ (17 ) Bausch Health Companies Inc. Organic Growth (non-GAAP) - by Segment For the Three Months Ended March 31, 2024 and 2023 (unaudited) Table 3 Calculation of Organic Revenue for the Three Months Ended March 31, 2024 March 31, 2023 Change in GAAP Revenues Change in Organic Revenue (in millions) Revenue as Reported Changes in Exchange Rates(a) Acquisitions Organic Revenue (Non-GAAP)(b) Revenue as Reported Divestitures and Dis-continuations Organic Revenue (Non-GAAP)(b) Amount Pct. Amount Pct. Bausch Health (excl. B+L) Salix $ 499 $ - $ - $ 499 $ 496 $ (9 ) $ 487 $ 3 1% $ 12 2% International 265 (14 ) - 251 247 (1 ) 246 18 7% 5 2% Solta Medical 88 2 - 90 73 - 73 15 21% 17 23% Diversified Neuro 103 - - 103 102 - 102 1 1% 1 1% Dermatology 50 - - 50 43 (3 ) 40 7 16% 10 25% Generics 25 - - 25 27 (3 ) 24 (2 ) (7)% 1 4% Dentistry 24 - - 24 25 - 25 (1 ) (4)% (1 ) (4)% Total Diversified 202 - - 202 197 (6 ) 191 5 3% 11 6% Bausch Health (excl. B+L) revenues 1,054 (12 ) - 1,042 1,013 (16 ) 997 41 4% 45 5% Bausch + Lomb Vision Care 635 18 (9 ) 644 587 (1 ) 586 48 8% 58 10% Surgical 197 1 - 198 183 - 183 14 8% 15 8% Pharmaceuticals 267 1 (79 ) 189 161 (1 ) 160 106 66% 29 18% Total Bausch + Lomb revenues 1,099 20 (88 ) 1,031 931 (2 ) 929 168 18% 102 11% Total Bausch Health Companies Inc. revenues $ 2,153 $ 8 $ (88 ) $ 2,073 $ 1,944 $ (18 ) $ 1,926 $ 209 11% $ 147 8% (a) The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period. (b) To supplement the financial measures prepared in accordance with GAAP, the Company uses certain non-GAAP financial measures. For additional information about the Company's use of such non-GAAP financial measures, refer to the body of the news release to which these tables are attached. Organic revenue (non-GAAP) for the three months ended March 31, 2024 is calculated as revenue as reported adjusted for the impact for changes in exchange rates (previously defined in this news release) and acquisitions. Organic revenue (non-GAAP) for the three months ended March 31, 2023 is calculated as revenue as reported less revenues attributable to divestitures and discontinuances during the twelve months prior to the day of divestiture or discontinuance, as there are no revenues from those businesses and assets included in the comparable current period. Bausch Health Companies Inc. Other Financial Information (unaudited) (in millions) March 31, 2024 December 31, 2023 Cash, Cash Equivalents and Restricted Cash Cash and cash equivalents $ 733 $ 947 Restricted cash 22 15 Cash, cash equivalents and restricted cash $ 755 $ 962 Debt Obligations Senior Secured Credit Facilities: Revolving Credit Facilities $ 300 $ 275 AR Credit Facility 325 350 Term Loan Facilities 5,235 5,273 Senior Secured Notes 9,305 9,305 Senior Unsecured Notes 5,540 5,791 Other 12 12 Total long-term debt and other, net of premiums, discounts and issuance costs 20,717 21,006 Plus: Unamortized premiums, discounts and issuance costs 1,357 1,382 Total long-term debt and other $ 22,074 $ 22,388 Maturities of Debt Obligations (at principal amount) Remainder of 2024 116 155 2025 2,675 2,790 2026 757 892 2027 6,773 6,748 2028 7,194 7,219 2029 1,609 1,609 2030 - 2031 1,593 1,593 Total debt obligations $ 20,717 $ 21,006 Three Months Ended March 31, 2024 2023 Cash provided by operating activities $ 211 $ 154 SOURCE: Bausch Health Companies Inc. View the original press release on accesswire.com